drugset / Trial / NCT04742023

Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation

NCT04742023

Phase 0 Completed 40 enrolled Northwell Health
RandomizedSingle-groupSingle-blindTreatment

Summary

This will be a prospective, randomized, single-blinded controlled trial in which the investigators evaluate post-operative serum glucose control using conventional point-of-care glucose monitoring in the morning and before meals (standard of care) versus continuous glucose monitoring using the Medtronic Guardian™ Sensor 3 continuous glucose monitor. The investigators will compare the average daily glucose level in the post-operative period (through post-operative day five) between the two arms in patients with diabetic nephropathy immediately post-renal transplant. This will serve as a pilot study to in order to power a main study.

Timeline

Start
2020-04-21
Primary completion
2023-11-21
Completion
2023-12-21

Drugs

EvaluationDrugModalityDoseRoute
Background Insulin Protein / enzyme biologic

Indications